MolDX's Non-NGS Cancer Panel LCD Takes Effect October 12: What Labs and RCM Teams Need to Know
Short answer: Starting October 12, 2026, MolDX contractors will apply a new LCD covering non-NGS targeted molecular panels for cancer therapy selection. Coverage requires guideline-recommended testing, no duplicate panel for the same indication, and either NGS being infeasible or results in under 10 business days from sample receipt, plus a completed MolDX Technical Assessment.
What is changing and when
The Medicare Coverage Database lists four final LCDs titled "MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Targeted Therapy in Cancer": L40210 (Palmetto GBA), L40222 (Noridian), L40226 (CGS), and L40278 (WPS). Each shows an effective date of October 12, 2026 and an "updated on" date of August 21, 2026. Noridian's Jurisdiction F notice announced the finalized policy alongside the hereditary thrombophilia LCD, noting that supporting billing and coding articles and responses to public comments were published with it.
The policy began as a proposal in September 2025. As Discoveries in Health Policy reported, the draft focused on rapid, multiplex PCR-based panels in non-small cell lung cancer and colorectal cancer and cited 81 references. The proposed title said "Predictive Testing in Cancer"; the final title says "Targeted Therapy in Cancer."
The coverage criteria in plain terms
According to the final LCD text in the Medicare Coverage Database, coverage applies only when all of the following are met. The patient has a cancer diagnosis where molecular testing informs treatment. The testing is recommended by national consensus guidelines. The patient has not had prior panel testing for the same indication or genetic content. And testing is feasible, meaning NGS is unavailable or the non-NGS test returns results quickly with comparable accuracy.
The policy also sets limitations. The test must accurately detect the most common genes and genomic positions required for FDA-approved therapies, and the LCD states that a negative result may be followed by NGS for additional genes. Tests must complete the MolDX Technical Assessment, which evaluates analytical validity, clinical validity and clinical utility, and tests using similar methodology must show equivalent or better performance. Examples of biomarkers named in the policy include EGFR, ALK, BRAF, KRAS, ROS1, RET, NTRK and MET exon 14 skipping, per the relevant national guidelines for each cancer type.
What changed between the proposal and the final LCD
The response-to-comments article (A60527) describes several clarifications that matter operationally:
- Turnaround clock. "Rapid" now means less than the ASCO-recommended 10 business days from sample receipt in the laboratory, rather than from sample acquisition.
- Concurrent ordering. Ordering both an NGS panel and a non-NGS panel for identical genetic content is considered duplicative, although later NGS may include genes beyond the non-NGS panel's scope.
- Clinical validity evidence. Laboratories need not independently publish clinical validity data if peer-reviewed evidence already supports the analytes and intended uses.
- Proteomic tests. Language was updated to acknowledge that proteomic tests may be considered if they meet all criteria.
Why the 10-business-day clock is the operational risk
Because the clock starts at sample receipt in the laboratory, labs control it only partly. Accessioning delays, send-out routing and batching schedules all eat into the window. A lab that runs a rapid panel only twice a week may meet the clinical promise of speed but fail the documentation test if turnaround is audited. Track receipt-to-result time per specimen, not as a monthly average, and be ready to show it.
The duplicate-content rule creates a second risk. If an oncologist orders a non-NGS panel and a comprehensive NGS profile on the same day for the same biomarkers, one of them is likely to be treated as duplicative. Order-entry logic that flags overlapping content before accessioning is cheaper than appealing the denial.
What labs and RCM teams should do before October 12
Check Technical Assessment status. Coverage depends on it. If your panel has not completed assessment, expect denials regardless of clinical picture. See our DEX Z-code guide for how assessed tests are identified on claims. The proposed LCD, as summarized by Discoveries in Health Policy, listed CPT 81479 with a DEX Z-code; confirm the final billing article for your contractor rather than assuming it carried over.
Map orders to guidelines. Requisitions should capture the cancer type and the guideline basis. Our denial-prevention guide and Medicare coverage overview explain how LCD criteria translate into documentation.
Build a prior-panel lookup. The no-prior-panel criterion requires knowing what was already run. That includes testing at other laboratories, which means asking the ordering clinician as well as searching your own records.
Plan the reflex pathway. The LCD expects that a negative non-NGS result may be followed by NGS. Document why the second test adds genes rather than repeating content. This sits alongside other MolDX oncology policy shifts, such as the hematologic malignancy NGS coverage changes and the hereditary thrombophilia LCD taking effect the same day.
Teams that want order-time checks against payer and contractor policy can see how ScreenMyGene approaches this on the ScreenMyGene homepage.
FAQ
When does the MolDX non-NGS targeted panel LCD take effect?
For services performed on or after October 12, 2026. The four contractor versions are L40210 (Palmetto GBA), L40222 (Noridian), L40226 (CGS) and L40278 (WPS). Each lists the same title and effective date. Confirm the version that applies to your jurisdiction and date of service before billing.
What counts as a rapid result under the LCD?
Less than the ASCO-recommended 10 business days from sample receipt in the laboratory. The final policy clarified that the clock starts at receipt in the lab, not at sample acquisition. Labs should track receipt-to-result time per specimen so they can document that the test met the rapid-result expectation if reviewed.
Can a lab order NGS and a non-NGS panel together?
Ordering both concurrently for identical genetic content is considered duplicative under the final LCD. Subsequent NGS can still be appropriate when it covers additional genes beyond the non-NGS panel, for example after a negative result. Document the reason the second test adds clinical information.
Does the test need a MolDX Technical Assessment?
Yes. The LCD requires tests to complete the MolDX Technical Assessment evaluating analytical validity, clinical validity and clinical utility. The final policy clarified that laboratories need not independently publish clinical validity data when peer-reviewed evidence already supports the analytes and intended uses of the test.
Which biomarkers does the policy expect panels to detect?
Tests must accurately detect the most common genes and genomic positions required for FDA-approved therapies. The policy names examples including EGFR, ALK, BRAF, KRAS, ROS1, RET, NTRK and MET exon 14 skipping, applied per the national guidelines for each cancer type. Panels missing guideline-expected content risk non-coverage.
This article is provided for general educational and business-decision-support purposes for laboratory, revenue-cycle and clinical-ordering professionals. It summarizes Medicare Coverage Database documents as they appeared on October 6, 2026, and is not legal, coding, compliance or reimbursement advice. Coverage policies change; verify the current LCD and billing article with your Medicare Administrative Contractor before acting.
Sources: CMS MCD, L40226 (CGS); L40222 (Noridian); L40210 (Palmetto GBA); L40278 (WPS); CMS MCD, Response to Comments A60527; Noridian JF Part B, finalized LCD notice; Discoveries in Health Policy, Sept 9, 2025.